Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2003 Nov;77(22):12336-45.
doi: 10.1128/jvi.77.22.12336-12345.2003.

Genetic and functional analysis of full-length human immunodeficiency virus type 1 env genes derived from brain and blood of patients with AIDS

Affiliations

Genetic and functional analysis of full-length human immunodeficiency virus type 1 env genes derived from brain and blood of patients with AIDS

Asa Ohagen et al. J Virol. 2003 Nov.

Abstract

The genetic evolution of human immunodeficiency virus type 1 (HIV-1) in the brain is distinct from that in lymphoid tissues, indicating tissue-specific compartmentalization of the virus. Few primary HIV-1 envelope glycoproteins (Envs) from uncultured brain tissues have been biologically well characterized. In this study, we analyzed 37 full-length env genes from uncultured brain biopsy and blood samples from four patients with AIDS. Phylogenetic analysis of intrapatient sequence sets showed distinct clustering of brain relative to blood env sequences. However, no brain-specific signature sequence was identified. Furthermore, there was no significant difference in the number or positions of N-linked glycosylation sites between brain and blood env sequences. The patterns of coreceptor usage were heterogeneous, with no clear distinction between brain and blood env clones. Nine Envs used CCR5 as a coreceptor, one used CXCR4, and two used both CCR5 and CXCR4 in cell-to-cell fusion assays. Eight Envs could also use CCR3, CCR8, GPR15, STRL33, Apj, and/or GPR1, but these coreceptors did not play a major role in virus entry into microglia. Recognition of epitopes by the 2F5, T30, AG10H9, F105, 17b, and C11 monoclonal antibodies varied among env clones, reflecting genetic and conformational heterogeneity. Envs from two patients contained 28 to 32 N-glycosylation sites in gp120, compared to around 25 in lab strains and well-characterized primary isolates. These results suggest that HIV-1 Envs in brain cannot be distinguished from those in blood on the basis of coreceptor usage or the number or positions of N-glycosylation sites, indicating that other properties underlie neurotropism. The study also demonstrates characteristics of primary HIV-1 Envs from uncultured tissues and implies that Env variants that are glycosylated more extensively than lab strains and well-characterized primary isolates should be considered during development of vaccines and neutralizing antibodies.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Amino acid alignment of primary HIV-1 Env clones from the blood (BL) and brains (BR) of four patients with AIDS (patients A through D) compared to that of the clade B consensus and to the 89.6 and ADA Env clones. Potential N-linked glycosylation sites are marked by shaded boxes. Epitopes recognized by monoclonal antibodies used for Western blotting, immunoprecipitation, and neutralization studies are underlined or indicated by the following symbols: open circle, F105; caret, 17b; open square, C11; filled circle, 2G12. The F105, 17b, C11, and 2G12 epitopes are discontinuous. Mutagenesis studies have shown that these monoclonal antibodies are sensitive to changes in gp160 at the following positions: (i) F105 is sensitive to changes at 256S, 257T, 368D, 370E, 384Y, 421K, 470P, 475M, 477D, 482Y, 483Y, and 484Y; (ii) 17b is sensitive to changes at 88N, 117K, 121K, 207K, 256S, 257T, 262N, V3 loop, 370E, 381E, 382F, 419R, 4201, 421K, 422Q, 432I, 427W, 435Y, 438P, and 475M; (iii) C11 is sensitive to changes at 45W, 88N, 491I, 493P, and 495G; and (iv) 2G12 is sensitive to changes at 295N, 297T, 334S, 386N, 392N, and 397N (reviewed in reference 47).
FIG. 1.
FIG. 1.
Amino acid alignment of primary HIV-1 Env clones from the blood (BL) and brains (BR) of four patients with AIDS (patients A through D) compared to that of the clade B consensus and to the 89.6 and ADA Env clones. Potential N-linked glycosylation sites are marked by shaded boxes. Epitopes recognized by monoclonal antibodies used for Western blotting, immunoprecipitation, and neutralization studies are underlined or indicated by the following symbols: open circle, F105; caret, 17b; open square, C11; filled circle, 2G12. The F105, 17b, C11, and 2G12 epitopes are discontinuous. Mutagenesis studies have shown that these monoclonal antibodies are sensitive to changes in gp160 at the following positions: (i) F105 is sensitive to changes at 256S, 257T, 368D, 370E, 384Y, 421K, 470P, 475M, 477D, 482Y, 483Y, and 484Y; (ii) 17b is sensitive to changes at 88N, 117K, 121K, 207K, 256S, 257T, 262N, V3 loop, 370E, 381E, 382F, 419R, 4201, 421K, 422Q, 432I, 427W, 435Y, 438P, and 475M; (iii) C11 is sensitive to changes at 45W, 88N, 491I, 493P, and 495G; and (iv) 2G12 is sensitive to changes at 295N, 297T, 334S, 386N, 392N, and 397N (reviewed in reference 47).
FIG. 2.
FIG. 2.
Phylogenetic analysis of full-length HIV-1 envelope gene sequences in blood and brain. The image is a PHYLIP neighbor-joining tree based on the F84 model used for PHYLIP maximum-likelihood trees. The color-coded regions represent the full-length gp160 env sequences cloned directly from blood and brain tissue from four patients with AIDS (patients A through D). The numbers associated with each branch represent their bootstrap values. Bootstrap resampling was done by using 100 replicates.
FIG. 3.
FIG. 3.
Effects of CCR5 and CXCR4 antibodies and inhibitors on virus replication in primary brain cultures. Chimeric NL4-3 viruses containing the aBR-01, aBL-01, dBR-02, or dBR-07 Envs or the 89.6, ADA, or SG3 control viruses were used to infect primary brain cultures in the absence or presence of 10 μg of CCR5 and CXCR4 monoclonal antibodies (2D7 and 12G5, respectively) per ml, 100 nM TAK-770, and/or 1.2 μM AMD3100, as indicated. HIV-1 replication was monitored by quantitating HIV-1 p24 in culture supernatants. The values represent the means of the results of two experiments (mean ± standard deviation, n = 2).
FIG. 4.
FIG. 4.
Virus neutralization assays. Luciferase reporter viruses pseudotyped with aBR-01, aBR-04-H, aBL-01, bBR-03-L, dBR-02, dBR-07, 89.6, ADA, or HXB2 Envs were preincubated with 30 μg of 17b or F105 antibodies or medium without antibodies per ml prior to infection of U87 cells transfected with CD4 and CXCR4 or CCR5. Luciferase activity was measured 48 h postinfection. The values represent the means of the results of two experiments (mean ± standard deviation, n = 2).

Similar articles

Cited by

References

    1. Albright, A. V., J. T. C. Shieh, T. Itoh, B. Lee, D. Pleasure, M. J. O'Connor, R. W. Doms, and F. Gonzalez-Scarano. 1999. Microglia express CCR5, CXCR4, and CCR3, but of these, CCR5 is the principal coreceptor for human immunodeficiency virus type 1 dementia isolates. J. Virol. 73:205-213. - PMC - PubMed
    1. Baba, M., O. Nishimura, N. Kanzaki, M. Okamoto, H. Sawada, Y. Iizawa, M. Shiraishi, Y. Aramaki, K. Okonogi, Y. Ogawa, and K. Meguro. 1999. A small molecule nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc. Natl. Acad. Sci. USA 96:5698-5703. - PMC - PubMed
    1. Berger, E. A., P. M. Murphy, and J. M. Farber. 1999. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu. Rev. Immunol. 17:657-700. - PubMed
    1. Buchacher, A., R. Predl, K. Strutzenberger, W. Steinfellner, A. Trkola, M. Purtscher, G. Gruber, C. Tauer, F. Steindl, A. Jungbauer, and H. Katinger. 1994. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res. Hum. Retrovir. 10:359-369. - PubMed
    1. Donaldson, Y. K., J. E. Bell, E. C. Holmes, E. S. Hughes, H. K. Brown, and P. Simmonds. 1994. In vivo distribution and cytopathology of variants of human immunodeficiency virus type 1 showing restricted sequence variability in the V3 loop. J. Virol. 68:5991-6005. - PMC - PubMed

Publication types